Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Domestic market and developing countries will need doses of Indian vaccines
Demand normalisation post the second wave contributed to the steady growth
Essential medicines were made available to more than 150 countries around the world during the pandemic
The resilient attitude of Indian pharmaceutical companies coupled with quick innovative solutions has ensured consistency in supply chains amid unprecedented challenges
The Department has been working continuously to ensure a stable long-term policy environment and reduce the compliance burden on the Industry.
Novelix will provide financial and infrastructural support for the entire technology transfer and scale-up program
Speakers for the Session are: Venkata Prasad K., Unit Head, Deepak Nitrite; Abhilash Pasham, Associate General Manager - Central Engineering & Projects, Dr. Reddy's Laboratories; C. V. Rajulu, Consultant, Industry; and Jyoti Shankar Jha, Senior Lead Scientist, Alleima India. The moderator for the Session is Pravin Prashant, Executive Editor, Indian Pharma Post
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
Subscribe To Our Newsletter & Stay Updated
